Comment: Management of De Novo Chronic Myelogenous Leukemia and Imatinib-Induced Acute Rhabdomyolysis With the Second-Generation Tyrosine Kinase Inhibitor Dasatinib

Basit Öğe Kaydı
dc.contributor.authorUz, Burak
dc.contributor.authorDolasik, Ilhan
dc.date.accessioned2024-08-04T20:57:27Z
dc.date.available2024-08-04T20:57:27Z
dc.date.issued2016
dc.departmentİnönü Üniversitesien_US
dc.description.abstract[Abstract Not Available]en_US
dc.identifier.doi10.1177/1060028015627663
dc.identifier.endpage335en_US
dc.identifier.issn1060-0280
dc.identifier.issn1542-6270
dc.identifier.issue4en_US
dc.identifier.pmid26839006en_US
dc.identifier.startpage334en_US
dc.identifier.urihttps://doi.org/10.1177/1060028015627663
dc.identifier.urihttps://hdl.handle.net/11616/102629
dc.identifier.volume50en_US
dc.identifier.wosWOS:000372717400014en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Incen_US
dc.relation.ispartofAnnals of Pharmacotherapyen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keywords]en_US
dc.titleComment: Management of De Novo Chronic Myelogenous Leukemia and Imatinib-Induced Acute Rhabdomyolysis With the Second-Generation Tyrosine Kinase Inhibitor Dasatiniben_US
dc.typeLetteren_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu